Medeon Biodesign, Inc. (TPEX:6499)

Medeon Biodesign Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	452.48	520.79	513.37	1,238	483.9	735.32
Short-Term Investments	465.32	656.96	652.18	862.1	1,025	1,608
Trading Asset Securities	38.53	42.12	41.66	41.93	37.87	6.48
Cash & Short-Term Investments	956.33	1,220	1,207	2,142	1,547	2,350
Cash Growth	19.83%	1.05%	-43.64%	38.44%	-34.16%	7.49%
Accounts Receivable	43.38	39.26	37.84	41.77	32.35	10.12
Other Receivables	10.47	7.17	7.71	8.37	26.65	5.12
Receivables	53.85	46.43	45.55	50.15	59.01	15.25
Inventory	30	24.84	34.1	10.77	10.06	-
Prepaid Expenses	35.24	-	-	24.89	21.42	24.68
Other Current Assets	3.18	31.02	30.34	-	-	-
Total Current Assets	1,079	1,322	1,317	2,228	1,638	2,390
Property, Plant & Equipment	284.87	267.83	355.47	321.82	340.24	44.52
Long-Term Investments	-	-	-	-	1,876	1,847
Goodwill	106.74	106.74	106.74	106.74	106.74	39.23
Other Intangible Assets	40.46	45.36	55.01	64.33	73.44	39.71
Long-Term Deferred Tax Assets	32.95	32.95	32.95	-	-	-
Other Long-Term Assets	7.69	4.77	10.37	26.46	5.59	4.58
Total Assets	1,551	1,780	1,878	2,747	4,040	4,364

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	8.13	7.55	12	5.36	3.94	0.05
Accrued Expenses	86.44	85.37	113.03	98.01	73.09	68.33
Current Portion of Leases	42.96	41.39	54.56	47.15	36.69	14.53
Current Income Taxes Payable	-	-	-	37.97	56.78	66.74
Current Unearned Revenue	9.23	7.94	4.51	3.11	0.86	0.65
Other Current Liabilities	17.42	18.7	31.54	30.16	27.17	10
Total Current Liabilities	164.18	160.96	215.64	221.76	198.51	160.3
Long-Term Leases	108.52	71.66	113.84	139.59	162.22	15.71
Long-Term Deferred Tax Liabilities	9.44	10.41	12.36	14.31	15.74	-
Total Liabilities	282.14	243.03	341.84	375.65	376.48	176

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	969.45	969.45	922.45	922.45	878.4	732.34
Additional Paid-In Capital	1,956	-	-	1,341	1,344	1,349
Retained Earnings	-1,743	-1,496	-792.94	31.25	1,355	2,072
Treasury Stock	-	-	-5.25	-10.6	-10.6	-10.6
Comprehensive Income & Other	46.71	2,002	1,396	36.18	30.94	-12.49
Total Common Equity	1,230	1,476	1,520	2,320	3,597	4,130
Minority Interest	39.39	61.03	15.71	51.51	66.1	58.15
Shareholders' Equity	1,269	1,537	1,536	2,371	3,664	4,188
Total Liabilities & Equity	1,551	1,780	1,878	2,747	4,040	4,364

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	151.49	113.05	168.4	186.74	198.91	30.24
Net Cash (Debt)	804.84	1,107	1,039	1,955	1,348	2,320
Net Cash Growth	21.61%	6.55%	-46.87%	45.01%	-41.87%	36.98%
Net Cash Per Share	8.50	11.99	11.27	21.24	14.65	25.19
Filing Date Shares Outstanding	96.94	96.94	92.14	92.04	92.02	92.02
Total Common Shares Outstanding	96.94	96.94	92.14	92.04	92.02	92.02
Working Capital	914.43	1,161	1,102	2,006	1,439	2,230
Book Value Per Share	12.69	15.22	16.50	25.21	39.10	44.89
Tangible Book Value	1,083	1,324	1,358	2,149	3,417	4,051
Tangible Book Value Per Share	11.17	13.65	14.74	23.35	37.14	44.03
Machinery	205.65	220.85	229.55	178.49	168.97	46.34
Leasehold Improvements	101.63	100.5	84.96	46.22	45.6	6.43

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 25, 2026

Data Sources Report a data error